세계의 경피 흡수형 스킨 패치 시장 - 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 유통 채널별, 지역별, 부문 예측(2024-2030년)

Transdermal Skin Patches Market Size, Share & Trends Analysis Report By Type (Multi-layer Drug-in-Adhesive), By Application (Pain Relief), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,830,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,315,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,283,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

경피 흡수형 스킨 패치 시장 동향

경피 흡수형 스킨 패치 세계 시장은 2023년에 78억 2,000만 달러로 추정되며, 2024-2030년에 걸쳐 CAGR 5.0%를 나타낼 것으로 예측됩니다. 심혈관 장애, 당뇨병, 만성 통증 등 만성 질환의 유병률 상승, 저침습 치료에 대한 소비자의 취향 증가, 세계 인구의 고령화, 경피 약물 전달 시스템의 기술 진보 등이 시장을 크게 밀어 올린다 있습니다.

경피 흡수형 스킨 패치는 기존의 경구 및 주사제를 대체하는 비침습적이고 편리한 대안을 설명합니다. 환자의 컴플라이언스를 향상시키고 경구 약물에 흔한 위장 부작용을 최소화할 수 있습니다. 이 사용 편의성과 장기간에 걸쳐 안정적인 약물 방출은 경피 흡수 스킨 패치를 만성 질환 관리에 특히 매력적으로 만듭니다.

이 시장은 주로 세계의 만성 질환의 유병률 증가로 큰 성장을 이루고 있습니다. 2024년 2월 발표된 CDC 보고서에 따르면 미국에서는 1억 2,900만 명이 암, 심장병, 비만, 당뇨병, 고혈압 등 적어도 하나의 주요 만성 질환을 앓고 있습니다. 만성 통증을 관리하려면 일반적으로 진통제의 정기적 인 투여가 필요하지만 경구 및 주사제는 부작용과 빈번한 투여가 필요하기 때문에 번거로울 수 있습니다.

경피 흡수형 스킨 패치는 장기간에 걸쳐 약물을 제어 방출함으로써 해결책을 제공하여 환자의 컴플라이언스를 향상시키고 치료 성적을 향상시킵니다. 예를 들어, 심한 만성 통증 관리에 사용되는 펜타닐 경피 흡수 스킨 패치는 약물을 72시간 동안 지속적으로 투여함으로써 빈번한 투여의 필요성을 감소시키고 안정된 통증 완화를 유지합니다.

마이크로니들, 이온토포레시스, 침투촉진제 등의 약물전달 시스템의 혁신은 경피투약의 범위를 크게 넓혀 고분자 및 생물제제에도 대응할 수 있게 되었습니다. 마이크로니들 패치는 피부에 미세한 홈을 만들어 경피 투여가 어려운 고분자 약물의 투여를 가능하게 합니다. 주목할만한 예는 당뇨병 환자에게 인슐린 투여를 위한 마이크로니들 패치입니다. 이것은 매일 주사를 대체하는 통증이없는 치료법이며 혈당 조절을 향상시킬 수 있습니다. 또 다른 획기적인 기술인 이온토포레시스(Iontophoresis)는 피부로부터의 약물 침투를 높이기 위해 미세한 전하를 이용합니다. 예를 들면, IontoPatch는 건염이나 활액포염 등의 치료에 항염증제를 투여하여 약물의 흡수와 효과를 높입니다. 이러한 진보는 경피 흡수 시스템의 효율성과 신뢰성을 높이고 새로운 치료 가능성을 도입함으로써 시장 성장을 가속하고 비 침습적 수단으로 치료 가능한 증상 범위를 확대합니다.

낮은 침습 치료에 대한 소비자의 선호도 증가가 시장을 크게 견인하고 있습니다. 환자와 의료 제공업체는 통증 완화, 감염 위험 감소, 경구 약물 및 주사보다 부작용이 적은 패치에 호의적입니다. 예를 들어, Biochemie Novartis의 호르몬 대체 요법용 패치 Estraderm Mx Patch는 호르몬을 안정적으로 방출하므로 경구 HRT에서 볼 수 있는 수준의 변동과 관련된 부작용을 최소화할 수 있습니다. 또한, 금연, 통증 관리, 신경 질환을위한 패치는 눈에 띄지 않고 편리한 약물 전달 방법을 설명합니다. 이 비침습적 접근은 환자의 안락함과 컴플라이언스를 향상시키고 이러한 장점에 대한 인식이 넓어짐에 따라 시장 성장을 뒷받침합니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 경피 흡수형 스킨 패치 시장의 변수, 동향, 범위

• 시장 계통의 전망
  • 모 시장 전망
  • 보조 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 경피 흡수형 스킨 패치 시장 : 유형, 추정·동향 분석

• 부문 대시보드
• 경피 흡수형 스킨 패치 시장 : 유형 변동 분석, 2023년과 2030년

제5장 경피 흡수형 스킨 패치 시장 : 용도, 추정·동향 분석

• 부문 대시보드
• 경피 흡수형 스킨 패치 시장 :용도 변동 분석, 2023년과 2030년

제6장 경피 흡수형 스킨 패치 시장 : 유통 채널, 추정·동향 분석

• 부문 대시보드
• 경피 흡수형 스킨 패치 시장 : 유통 채널 변동 분석, 2023년과 2030년

제7장 경피 흡수형 스킨 패치 시장 : 지역별, 추정·동향 분석

• 지역별 시장 점유율 분석, 2023년과 2030년
• 지역별 시장 대시보드
• 세계 지역 시장 현황
• 시장 규모, 예측 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
• 기업/경쟁의 분류
• 벤더 상황
  • 주요 기업의 시장 점유율 분석, 2023년
  • Teva Pharmaceutical Industries Ltd
  • Novartis AG
  • Teikoku Pharma USA Inc.
  • Viatris Inc.
  • Johnson &Johnson
  • Luye Pharma Group
  • Purdue Pharma Manufacturing LP
  • Henan Lingrui Pharmaceutical Ltd
  • Samyang Biopharmaceuticals Corp.
  • Hisamitsu Pharmaceutical Co, Inc.

JHS

영문 목차

영문목차

Transdermal Skin Patches Market Trends

The global transdermal skin patches market was estimated at USD 7.82 billion in 2023 and is projected to grow at a CAGR of 5.0% from 2024 to 2030. The rising prevalence of chronic diseases such as cardiovascular disorders, diabetes, chronic pain, etc., increased consumer preference for minimally invasive treatment, the aging global population, and technological advancements in transdermal drug delivery systems have significantly boosted the market.

Transdermal patches provide a noninvasive, convenient alternative to traditional oral and injectable medications. They enhance patient compliance and minimize the gastrointestinal side effects that often accompany oral drugs. This ease of use and consistent drug release over extended periods make transdermal patches particularly attractive for managing chronic conditions.

The market is experiencing significant growth, primarily driven by the increasing prevalence of chronic diseases worldwide. According to the CDC report published in February 2024, an estimated 129 million people in the U.S. have at least 1 major chronic disease, such as cancer, heart disease, obesity, diabetes, and hypertension. Managing chronic pain typically involves regular administration of pain relief medication, which can be cumbersome with oral or injectable forms due to their side effects and the need for frequent dosing.

Transdermal patches offer a solution by providing a controlled release of medication over extended periods, which enhances patient compliance and improves therapeutic outcomes. For instance, the fentanyl transdermal patch, used for managing severe chronic pain, delivers the drug continuously for 72 hours, reducing the need for frequent dosing and maintaining steady pain relief.

Innovations in drug delivery systems, including microneedles, iontophoresis, and permeation enhancers, have significantly broadened the scope of transdermal medication delivery, accommodating large molecules and biologics. Microneedle patches create microscopic channels in the skin, enabling the administration of large molecule drugs that are otherwise difficult to deliver transdermal. A notable example is the microneedle patch for insulin delivery in diabetic patients, which offers a painless alternative to daily injections, potentially improving glycemic control. Iontophoresis, another breakthrough technology, employs a small electric charge to enhance drug penetration through the skin. For instance, IontoPatch delivers anti-inflammatory drugs to treat conditions like tendinitis and bursitis, increasing the drug's absorption and effectiveness. These advancements boost the efficiency and reliability of transdermal delivery systems and introduce new therapeutic possibilities, driving market growth and expanding the range of treatable conditions through non-invasive means.

The rising consumer preference for minimally invasive treatments significantly drives the market. Patients and healthcare providers favor these patches for reduced pain, lower infection risk, and fewer side effects than oral medications or injections. For instance, hormone replacement therapy patches Estraderm Mx Patch by Biochemie Novartis offer a steady hormone release, minimizing side effects linked to fluctuating levels seen with oral HRT. In addition, patches for smoking cessation, pain management, and neurological disorders provide a discreet and convenient drug delivery method. This non-invasive approach enhances patient comfort and compliance, boosting the market growth as awareness of these benefits spreads.

Global Transdermal Skin Patches Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global transdermal skin patches market based on type, application, distribution channel, and region:

• Type Outlook (Revenue, USD Billion, 2018 - 2030)
• Single-layer Drug-in-Adhesive
• Multi-layer Drug-in-Adhesive
• Matrix
• Other Types
• Application Outlook (Revenue, USD Billion, 2018 - 2030)
• Pain Relief
• Smoking Reduction and Cessation Aid
• Cardiovascular Disorders
• Neurological Disorders
• Hormonal Therapy
• Other Applications
• Distribution Channel Outlook (Revenue, USD Billion, 2018 - 2030)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Outlook (Revenue, USD Billion, 2018 - 2030)
• North America

U.S.

Canada

Mexico

• Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

• Asia Pacific

Japan

China

India

South Korea

Australia

Thailand

• Latin America

Brazil

Argentina

• Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Application
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Application Outlook
  • 2.2.3. Distribution Channel Outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Transdermal Skin Patches Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
  • 3.2.3. Industry Analysis - Porter's
    • 3.2.3.1. Bargaining power of the suppliers
    • 3.2.3.2. Bargaining power of the buyers
    • 3.2.3.3. Threats of substitution
    • 3.2.3.4. Threats from new entrants
    • 3.2.3.5. Competitive rivalry
  • 3.2.4. PESTEL Analysis
    • 3.2.4.1. Political landscape
    • 3.2.4.2. Economic and Social landscape
    • 3.2.4.3. Technological landscape

Chapter 4. Transdermal Skin Patches Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Transdermal Skin Patches Market: Type Movement Analysis, 2023 & 2030 (USD Billion)
  • 4.2.1. Single-layer Drug-in-Adhesive
    • 4.2.1.1. Single-layer Drug-in-Adhesive Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.2.2. Multi-layer Drug-in-Adhesive
    • 4.2.2.1. Multi-layer Drug-in-Adhesive Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.2.3. Matrix
    • 4.2.3.1. Matrix Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.2.4. Other Types
    • 4.2.4.1. Other Types Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Transdermal Skin Patches Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Transdermal Skin Patches Market: Application Movement Analysis, 2023 & 2030 (USD Billion)
  • 5.2.1. Pain Relief
    • 5.2.1.1. Pain Relief Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.2.2. Smoking Reduction
    • 5.2.2.1. Smoking Reduction Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.2.3. Cardiovascular Disorders
    • 5.2.3.1. Cardiovascular Disorders Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.2.4. Neurological Disorders
    • 5.2.4.1. Neurological Disorders Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.2.5. Hormonal Therapy
    • 5.2.5.1. Hormonal Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.2.6. Other Applications
    • 5.2.6.1. Other Applications Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Transdermal Skin Patches Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Transdermal Skin Patches Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Billion)
  • 6.2.1. Hospital Pharmacies
    • 6.2.1.1. Hospital Pharmacies Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 6.2.2. Retail Pharmacies
    • 6.2.2.1. Retail Pharmacies Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 6.2.3. Online Pharmacies
    • 6.2.3.1. Online Pharmacies Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Transdermal Skin Patches Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2023 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Billion)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. UK market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. France market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/ reimbursement structure
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/ reimbursement structure
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Billion)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. China market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. India market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/ reimbursement structure
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Billion)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Billion)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework/ reimbursement structure
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/ reimbursement structure
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/ reimbursement structure
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/ reimbursement structure
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Billion)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company market share analysis, 2023
  • 8.3.2. Teva Pharmaceutical Industries Ltd
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Type benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Novartis AG
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Type benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. Teikoku Pharma USA Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Type benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Viatris Inc.
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Type benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Johnson & Johnson
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Type benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Luye Pharma Group
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Type benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Purdue Pharma Manufacturing LP
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Type benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Henan Lingrui Pharmaceutical Ltd
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Type benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Samyang Biopharmaceuticals Corp.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Type benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Hisamitsu Pharmaceutical Co, Inc.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Type benchmarking
    • 8.3.11.4. Strategic initiatives

관련자료